August 25, 1999

Association of the CCR5Δ32 Mutation With Improved Response to Antiretroviral Therapy

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

JAMA. 1999;282(8):734. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-8-jbk0825

To the Editor: Individuals infected with human immunodeficiency virus type 1 (HIV-1) who are treated with highly active antiretroviral therapy (HAART), including HIV-1 protease inhibitors, experience dramatic benefits.1 However, virologic failure occurs commonly in clinical trials and in practice.2,3 The CCR5Δ32 mutation is associated with decreased susceptibility to HIV-1 infection (Δ32/Δ32) and slower progression to acquired immunodeficiency syndrome (wild type [wt]/Δ32).4 We wished to determine whether the presence of the CCR5Δ32 allele would affect virologic outcome after HAART is initiated.

First Page Preview View Large
First page PDF preview
First page PDF preview